Skip to main content
Premium Trial:

Request an Annual Quote

GeneProt to Build Proteomics Facility and Relocate Headquarters to New Jersey

NEW YORK, Oct. 3 – GeneProt said Wednesday that it will build a high-throughput proteomics laboratory in North Brunswick, NJ, and relocate its corporate headquarters there from Evanston, Ill.

The new facility, located in The Technology Center, a corporate complex owned by the New Jersey Economic Development Authority (NJEDA), will contain instruments and equipment for separating and analyzing proteins, including supercomputing equipment, GeneProt said in a statement.

GeneProt has leased 60,000 square feet of laboratory space in a building still under construction, and will finance the construction of an additional 40,000 square foot, four-story office building for its corporate headquarters. For its immediate needs, the company has leased 3,200 square feet of office space in the complex. 

To encourage the company to relocate to New Jersey, the NJEDA granted the company a construction allowance of $6 million, and an employment incentive grant worth over $3 million over 10 years. "This greatly supports our speed-to-market strategy and allows us to apply resources elsewhere; for example, in recruitment and R&D,” Cédric Loiret-Bernal, GeneProt CEO, said in a statement.

Earlier this year, GeneProt opened its first proteomics analysis facility in Geneva, Switzerland, that holds 51 Bruker Daltonics mass spectrometers for identifying the amino acid sequence of proteins isolated from clinical samples. The company is currently working with Novartis to perform proteomics studies on Novartis’ clinical samples.

The laboratory and corporate offices in North Brunswick will eventually hold about 150 GeneProt employees, the company said. The new facility will be fully operational in early 2002. 

GeneProt chose the new location, near Princeton, NJ, because of its proximity to Princeton University and other academic centers, and because it also close to large pharmaceutical companies located in central New Jersey, the company said.  
The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.